KR101683643B1 - 시아이에스-단일불포화 지방산의 알파-유도체 및 이의 의약으로서의 용도 - Google Patents

시아이에스-단일불포화 지방산의 알파-유도체 및 이의 의약으로서의 용도 Download PDF

Info

Publication number
KR101683643B1
KR101683643B1 KR1020117014462A KR20117014462A KR101683643B1 KR 101683643 B1 KR101683643 B1 KR 101683643B1 KR 1020117014462 A KR1020117014462 A KR 1020117014462A KR 20117014462 A KR20117014462 A KR 20117014462A KR 101683643 B1 KR101683643 B1 KR 101683643B1
Authority
KR
South Korea
Prior art keywords
cis
octadecenoic acid
hydroxy
ohod
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117014462A
Other languages
English (en)
Korean (ko)
Other versions
KR20110126100A (ko
Inventor
파블로 비쎈테 에스크바 루이츠
사비에르 부스꾸에츠 사우벳
그웬돌린 바르셀로 코브린
빅토리아 라도 카넬라스
라파엘 알바레즈 마르티네즈
실비아 테레스 히메네스
다니엘 로페즈
후아나 바르쎌로 에스다르엘라스
그린 줄리안 테일러
게라르도 아빌라 마르틴
Original Assignee
유니버시다드 데 레스 일레스 발레아르스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42242375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101683643(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 유니버시다드 데 레스 일레스 발레아르스 filed Critical 유니버시다드 데 레스 일레스 발레아르스
Publication of KR20110126100A publication Critical patent/KR20110126100A/ko
Application granted granted Critical
Publication of KR101683643B1 publication Critical patent/KR101683643B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
KR1020117014462A 2008-12-09 2009-12-04 시아이에스-단일불포화 지방산의 알파-유도체 및 이의 의약으로서의 용도 Expired - Fee Related KR101683643B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200803480A ES2342997B1 (es) 2008-12-09 2008-12-09 Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ESP200803480 2008-12-09
PCT/ES2009/070561 WO2010066931A1 (es) 2008-12-09 2009-12-04 Alfa-derivados de ácidos grasos cis-monoinsaturados para ser usados como medicamento

Publications (2)

Publication Number Publication Date
KR20110126100A KR20110126100A (ko) 2011-11-22
KR101683643B1 true KR101683643B1 (ko) 2016-12-07

Family

ID=42242375

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117014462A Expired - Fee Related KR101683643B1 (ko) 2008-12-09 2009-12-04 시아이에스-단일불포화 지방산의 알파-유도체 및 이의 의약으로서의 용도

Country Status (18)

Country Link
US (3) US9000042B2 (https=)
EP (4) EP2842555B1 (https=)
JP (2) JP5711140B2 (https=)
KR (1) KR101683643B1 (https=)
CN (1) CN102355897B (https=)
AU (6) AU2009326993B2 (https=)
BR (1) BRPI0922870A8 (https=)
CA (1) CA2745052C (https=)
DK (3) DK2842556T3 (https=)
ES (5) ES2342997B1 (https=)
HU (2) HUE056170T2 (https=)
IL (1) IL213354A (https=)
MX (1) MX2011005978A (https=)
PL (3) PL3366285T3 (https=)
PT (4) PT2374453E (https=)
RU (1) RU2531353C2 (https=)
SI (1) SI3366285T1 (https=)
WO (1) WO2010066931A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
WO2011089265A1 (en) * 2010-01-25 2011-07-28 Bridge Bioresearch Plc Use of fatty acid compounds for lowering blood glucose levels
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2013132092A1 (en) * 2012-03-09 2013-09-12 Pensieve International Plc Use of monounsaturated fatty acid compounds for controlling the body weight of a dog or a cat
WO2016062746A1 (en) * 2014-10-21 2016-04-28 Universitat De Les Illes Balears Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases
WO2019099664A1 (en) * 2017-11-16 2019-05-23 The Research Foundation For The State University Of New York Use of 2-hydroxyoleic acid for the treatment of systemic lupus erythematosus and other immune pathologies
CN115052852A (zh) * 2020-01-29 2022-09-13 巴利阿里群岛大学 α-羟基化脂肪酸代谢产物、其医学用途以及作为生物标志物的用途
ES2911474B2 (es) * 2020-11-17 2023-02-06 Univ Illes Balears Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
US12440467B2 (en) * 2021-12-09 2025-10-14 The Florida International University Board Of Trustees Treatment and prevention of infections using vegetable oil-derived polyols

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4928172B1 (https=) * 1969-10-27 1974-07-24
CH558321A (de) * 1971-08-03 1975-01-31 Ciba Geigy Ag Verfahren zur herstellung von carbonsaeuren bezw. carbonsaeuresalzen.
US3931306A (en) * 1973-10-23 1976-01-06 International Flavors & Fragrances Inc. Process for producing isomer mixtures containing high proportions of cis-2-methyl-3-pentenoic acid
DE2448339A1 (de) * 1974-10-10 1976-04-22 Basf Ag Verfahren zur herstellung von olefinisch ungesaettigten carbonsaeureestern
DE2559201B2 (de) * 1975-12-30 1978-06-15 Hoechst Ag, 6000 Frankfurt Organozinnverbindungen und ihre Verwendung als Stabilisatoren
US4241097A (en) * 1979-09-13 1980-12-23 International Flavors & Fragrances Inc. Use of benzodionones in augmenting or enhancing the aroma and taste of a foodstuff
US4391757A (en) * 1981-11-27 1983-07-05 Carstab Corporation Organic antimony containing stabilizer compositions for halogenated polymers
JPS5899432A (ja) * 1981-12-09 1983-06-13 Maruzen Sekiyu Kagaku Kk 不飽和脂肪酸またはその塩およびそれからなる抗菌剤
US4551279A (en) * 1984-01-09 1985-11-05 G. D. Searle & Co. Protease inhibitors
FR2609032B1 (fr) * 1986-12-30 1990-01-05 Centre Nat Rech Scient Epoxydes fonctionnels enantiomeriquement purs, leur procede de preparation et leur application comme synthons chiraux
US4808403A (en) * 1987-03-17 1989-02-28 International Flavors & Fragrances Inc. Use of N,N-diethyl-m-toluamide and/or the ethyl ester of 2-methyl-3-pentenoic acid as insect attractants
US5504107A (en) 1990-01-12 1996-04-02 The Ohio State University Research Foundation Optically pure 4-alkenyl- or 4-alkanyl-2-hydroxytetronic acids and pharmaceutical use thereof
GB9003201D0 (en) * 1990-02-13 1990-04-11 Unilever Plc Cosmetic composition
US5208260A (en) * 1990-03-29 1993-05-04 G. D. Searle & Co. Vinyl Glycine derivatives for memory and learning enhancement or treatment of a cognitive disorder
US5198250A (en) * 1990-07-16 1993-03-30 Lipotech Partners Limited Partnership Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
ES2039336T3 (es) * 1991-04-10 1999-08-01 Yu Ruey J Uso de composiciones cosmeticas que contienen acidos 2-hidroxicarboxilicos y compuestos afines para aliviar los indicios de cambios de las uñas.
US6300373B1 (en) 1993-09-10 2001-10-09 American Biogenetic Sciences, Inc. Antiproliferative and neurotrophic molecules
JP3489703B2 (ja) * 1995-10-23 2004-01-26 株式会社ノエビア 微細エマルション組成物
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
JPH10182338A (ja) * 1996-12-20 1998-07-07 Noevir Co Ltd 水中油型乳化組成物
JP2001523695A (ja) * 1997-11-24 2001-11-27 ザ スクリップス リサーチ インスティテュート ギャップ結合連絡の阻害剤
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
GB2385589A (en) * 2000-08-07 2003-08-27 Sofitech Nv Surfactant
ES2186576B1 (es) 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6702756B2 (en) * 2001-12-11 2004-03-09 University Technologies International Inc. Method and apparatus for diagnosing neurological impairment
BR0306957A (pt) 2002-01-22 2004-12-14 Syngenta Participations Ag Herbicidas
US7462349B2 (en) * 2002-10-24 2008-12-09 Nurit Kalderon Beta interferon for the treatment of chronic spinal cord injury
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
EP1622633B1 (en) * 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
ES2229935B1 (es) * 2003-10-10 2006-10-01 Universitat De Les Illes Balears Utilizacion del acido hidroxioleico y compuestos analagos del mismo como aditivos alimentarios funcionales.
KR100756890B1 (ko) * 2005-08-19 2007-09-07 경희대학교 산학협력단 신경세포 보호활성을 갖는 올레산을 함유하는 조성물
JP2009051732A (ja) * 2005-12-13 2009-03-12 Meiji Seika Kaisha Ltd Ｐｐａｒリガンド活性を有する組成物
WO2009127009A1 (en) 2008-04-18 2009-10-22 Commonwealth Scientific And Industrial Research Organisation Condensation polymers
JP2011516697A (ja) 2008-04-18 2011-05-26 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション ポリウレタン
ES2342997B1 (es) 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.

Also Published As

Publication number Publication date
DK2842556T3 (en) 2018-03-26
DK2374453T3 (en) 2015-03-30
MX2011005978A (es) 2011-10-11
US20150297548A1 (en) 2015-10-22
EP2842556A3 (en) 2015-08-05
ES2535498T8 (es) 2016-08-19
CN102355897A (zh) 2012-02-15
US10588883B2 (en) 2020-03-17
JP5711140B2 (ja) 2015-04-30
EP2842556A2 (en) 2015-03-04
IL213354A0 (en) 2011-07-31
AU2018229474B2 (en) 2019-08-22
IL213354A (en) 2017-06-29
EP2842556B1 (en) 2018-01-31
EP2842555A3 (en) 2015-04-15
HUE037396T2 (hu) 2018-08-28
AU2016228167A1 (en) 2016-09-29
WO2010066931A1 (es) 2010-06-17
KR20110126100A (ko) 2011-11-22
US9000042B2 (en) 2015-04-07
AU2018229472B2 (en) 2019-07-18
EP3366285B1 (en) 2021-06-30
WO2010066931A4 (es) 2010-08-05
ES2673406T3 (es) 2018-06-21
PT2842555T (pt) 2018-07-06
PL2374453T3 (pl) 2015-07-31
AU2019222955A1 (en) 2019-09-19
HUE056170T2 (hu) 2022-01-28
BRPI0922870A8 (pt) 2017-12-26
EP3366285A1 (en) 2018-08-29
SI3366285T1 (sl) 2021-11-30
ES2342997B1 (es) 2011-06-06
JP2012511510A (ja) 2012-05-24
EP2842555B1 (en) 2018-04-18
AU2016228171A1 (en) 2016-09-29
EP2374453A4 (en) 2012-05-30
DK3366285T3 (da) 2021-10-04
ES2661412T3 (es) 2018-03-28
ES2535498T3 (es) 2015-05-12
ES2899274T3 (es) 2022-03-10
EP2374453B1 (en) 2015-02-18
CA2745052A1 (en) 2010-06-17
US9730906B2 (en) 2017-08-15
AU2018229474A1 (en) 2018-10-04
PL3366285T3 (pl) 2022-01-10
US20180193297A1 (en) 2018-07-12
ES2342997A1 (es) 2010-07-20
CN102355897B (zh) 2014-06-04
BRPI0922870A2 (pt) 2016-01-12
AU2018229472A1 (en) 2018-10-04
AU2009326993B2 (en) 2016-06-16
PT3366285T (pt) 2021-10-07
RU2531353C2 (ru) 2014-10-20
EP2842555A2 (en) 2015-03-04
JP2015061856A (ja) 2015-04-02
PL2842556T3 (pl) 2018-07-31
US20110294883A1 (en) 2011-12-01
AU2009326993A1 (en) 2011-07-07
EP2374453A1 (en) 2011-10-12
CA2745052C (en) 2017-11-07
PT2374453E (pt) 2015-04-28
PT2842556T (pt) 2018-03-19
RU2011128335A (ru) 2013-01-20
AU2019222955B2 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
KR101683643B1 (ko) 시아이에스-단일불포화 지방산의 알파-유도체 및 이의 의약으로서의 용도
US11253497B2 (en) Use of derivatives of polyunsaturated fatty acids as medicaments

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211202

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

K11-X000 Ip right revival requested

St.27 status event code: A-6-4-K10-K11-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211202

PR0401 Registration of restoration

St.27 status event code: A-6-4-K10-K13-oth-PR0401

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R401 Registration of restoration
PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10